Immatics (IMTX) EPS (Basic) (2019 - 2025)

Immatics (IMTX) posted EPS (Basic) of -$0.34 for Q4 2025, up 31.0% sequentially from -$0.49 in Q3 2025, and down 174.35% YoY from $0.45 in Q4 2024.

Immatics (IMTX) EPS (Basic) (2019 - 2025) Analysis & Trends

Immatics has reported EPS (Basic) for 7 years, with the latest figure at -$0.34 in Q4 2025.

Quarterly EPS (Basic) fell 174.35% year-over-year to -$0.34 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.83 (down 1397.12% YoY) and the FY2025 annual result came in at -$1.81, down 1264.64% from the prior year.
EPS (Basic) improved to -$0.34 in Q4 2025 per IMTX's latest filing, from -$0.49 in the prior quarter.
Over five years, EPS (Basic) peaked at $1.53 in Q1 2022 and troughed at -$0.66 in Q2 2025.
A 5-year average of -$0.17 and a median of -$0.32 in 2022 frame the typical range for EPS (Basic).
The sharpest annual moves came in 2022 and 2025: EPS (Basic) soared 449.28% in 2022, then plunged 109706725.86% in 2025.
Over 5 years, EPS (Basic) stood at -$0.31 in 2021, then soared by 111.02% to $0.03 in 2022, then tumbled by 1138.03% to -$0.35 in 2023, then surged by 229.8% to $0.45 in 2024, then sank by 174.35% to -$0.34 in 2025.
According to Business Quant data, EPS (Basic) over the past three periods registered -$0.34, -$0.49, and -$0.66 for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	12.62
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	7.59
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-3.06
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.16
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	0.00
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.18
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	1.23
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.06
10	Immatics	1.27 Bn	719.31 Mn	-	-12.49

Download Data